ClinicalTrials.gg
RecruitingNCT05327608Updated Sep 3, 2026

Time Restricted Eating for the Improvement of Outcomes in Patients With Stage I-III Breast Cancer Receiving Chemotherapy Before Surgery

An interventional study of Short-Term Fasting and Chemotherapy in Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8 and Anatomic Stage III Breast Cancer AJCC v8, sponsored by Thomas Jefferson University. Recruiting at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-03.

Sponsored by Thomas Jefferson University · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Started Jul 2022; still recruiting 4 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
55
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 20 studies in Breast Neoplasms by Thomas Jefferson University — 4 open to participants now, 5 under way, none of them phase 3. Breast Neoplasms · Thomas Jefferson University.

Planned enrollment
5th of 15
55 · median 25
Started
2022
with 3 others
No phase
10 of 20
2 open now
Registered
12th of 20
by date

Among the 20 studies in Breast Neoplasms by Thomas Jefferson University, this one is the 5th largest by planned enrollment of the 15 interventional ones that give a count, is one of 4 that started in 2022, is one of 10 with no phase, and was the 12th registered.

Breast Neoplasms

14,843 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

4 of the 20 studies in Breast Neoplasms by Thomas Jefferson University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,573 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Breast Neoplasms by Thomas Jefferson University, or all of them as a file.
02

Study summary

This phase II trial studies whether time restricted eating (TRE) works to improve outcomes in patients with stage I-III breast cancer receiving chemotherapy before surgery (neoadjuvant) with a body mass index (BMI) 25-40. TRE has been shown to elicit similar metabolic changes as calorie restriction such as reduction in blood glucose levels, improved insulin sensitivity, and reduction of tumor cell growth. TRE may improve outcomes in patients with breast cancer.

Read the detailed description

PRIMARY OBJECTIVE:

I. To evaluate the proportion of patients that can adhere to TRE in patients with early stage breast cancer who receive neoadjuvant chemotherapy (NCT) for a new diagnosis of stage I-III breast cancer.

SECONDARY OBJECTIVES:

I. To evaluate the pathologic complete response (pCR) rate of TRE in patients with early stage breast cancer who receive neoadjuvant chemotherapy (NCT) for a new diagnosis of stage I-III breast cancer.

II. To evaluate the effect of TRE in the weight management (prevention of weight gain), measured by BMI and waist circumference, in patients who are undergoing neoadjuvant chemotherapy.

III. To evaluate the percent of patients who develop Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 grade 3 or 4 toxicities IV. To evaluate the differences in the pCR rate among breast cancer patients within different race/ethnic groups, African American versus (vs.) Non-Hispanic White (AA vs NHW) and based on baseline social determinants of health when undergoing NCT.

V. To evaluate if study intervention acceptability, adherence, and engagement differ by race (AA vs NHW) and based on baseline social determinants of health.

VI. To evaluate if percent of patients with CTCAE version 5.0 grade 3 or 4 toxicities differ by race (AA vs NHW) and based on baseline social determinants of health.

EXPLORATORY OBJECTIVE:

I. To monitor changes in the following inflammatory markers in patients undergoing neoadjuvant chemotherapy with TRE: fasting glucose, hemoglobin A1c, insulin, C-peptide, C-reactive protein (CRP), leptin, adiponectin, insulin-like growth factor 1 (IGF-1), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and free fatty acids and lipids.

OUTLINE:

Patients undergo TRE involving 16 hours of fasting and 8 hours of eating for 4 months while undergoing standard of care neoadjuvant chemotherapy. Patients also undergo blood sample collection on study.

After completion of study treatment, patients are followed up for 6 months.

03

Conditions studied

  • Anatomic Stage I Breast Cancer AJCC v8
  • Anatomic Stage II Breast Cancer AJCC v8
  • Anatomic Stage III Breast Cancer AJCC v8
  • Invasive Breast Carcinoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient must be >= 18 years of age at time of consent and must be able to understand and provide
  • 25-40 at time of enrollment
  • Patients must have an (ECOG) performance status of 0 or 1
  • Patient must have a recent diagnosis of confirmed primary invasive breast carcinoma

    * Oligometastatic disease is allowed if treating physician recommends standard chemotherapy

  • Patients must have clinical stage I-III (utilizing tumor, node, [TNM] criterion) at diagnosis
  • Clinical T size must be >= 1.5 cm if there is no radiographic or clinical evidence of axillary lymph node involvement. Any size tumor is allowed if axillary lymph nodes appear to be involved
  • Patient must be willing and able (have no ) to receive recommended standard neoadjuvant therapy consisting of at least 16 weeks of planned neoadjuvant chemotherapy
  • Patients must have organ and marrow function adequate for initiating neoadjuvant chemotherapy as determined by their treating physician
  • Patient must be willing and able (have no contraindication) to participate in TRE consisting of 16 weeks
  • Women of and sexually active males must use accepted and effective method(s) of or abstain from sexual intercourse for the duration of their participation in the study and for 6 months after the last study intervention
  • Patient must have a personal email address, an internet-capable device, and the ability/ willingness to read and reply to email every day for the duration of the study

Exclusion criteria

EXCLUSION CRITERIA:

  • Clinical T4 and/or N3 disease, including inflammatory breast cancer
  • Any prior treatment for the current breast cancer diagnosis, including surgery, chemotherapy, radiation, or experimental therapy
  • Women must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used. Patients must also not expect to conceive from the time of registration, while on study treatment, and until at least 6 months after the last study intervention
  • Patients with type 1 diabetes, or type 2 diabetes treated with insulin
  • Patients with a history of eating disorder
  • Patients who work on a rotating shift schedule
  • Patients must not have impaired decision-making capacity
  • Patients who are not English speaking as study staff is only able to provide the study intervention measurement tool
  • Patients that are > 2 weeks into starting chemotherapy regimen
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
55 participants (estimated)

Study arms

  • Experimental
    Treatment (TRE)

    Patients undergo TRE involving 16 hours of fasting and 8 hours of eating for 4 months while undergoing standard of care neoadjuvant chemotherapy. Patients also undergo blood sample collection on study.

    Other: Short-Term Fasting · Drug: Chemotherapy · Procedure: Biospecimen Collection · Other: Questionnaire Administration

Interventions

  • OtherShort-Term Fasting

    Undergo TRE

    Also known as: Intermittent Fasting, Short-term Intermittent Fasting

  • DrugChemotherapy

    Receive standard of care neoadjuvant chemotherapy

    Also known as: Chemo, Chemotherapy (NOS), Cancer, General

  • ProcedureBiospecimen Collection

    Undergo blood sample collection

    Also known as: Biological Sample, Collection, Biospecimen, Collected, Biospecimen, Collection, Sample, Collection, Specimen, Collection

  • OtherQuestionnaire Administration

    Ancillary studies

06

What researchers measure

Primary outcomes

  1. Proportion of patients who can adhere to time restricted eating (TRE) >= 70% of days

    The proportion of patients that adhere to TRE will be estimated with the corresponding exact binomial 90% confidence interval.

    Time frame: While undergoing neoadjuvant chemotherapy

Secondary outcomes

  1. Pathologic complete response (pCR) rate

    Will be estimated with corresponding the exact binomial 90% confidence intervals.

    Time frame: Up to 4 months

  2. Percent of patients who maintain or have a reduced body mass index and waist circumference

    Will be estimated with corresponding the exact binomial 90% confidence intervals.

    Time frame: Up to 4 months

  3. Percent of patients who develop grade 3 or 4 toxicities

    Will be assessed using Common Terminology Criteria for Adverse Event (CTCAE) version (v) 5.0.

    Time frame: Up to 4 months

  4. Social determinants of health

    Will be summarized descriptively for the entire study population and separately by the treatment received.

    Time frame: Up to 4 months

  5. pCR rate among Non-Hispanic White patients

    Will be tabulated estimated with corresponding the exact binomial 90% confidence intervals for entire study population and separately by the treatment received.

    Time frame: Up to 4 months

  6. Acceptability, adherence, and engagement of TRE among African American versus Non-Hispanic White breast cancer patients

    Time frame: Up to 4 months

  7. Incidence of adverse events

    Will assess percent of patients with CTCAE v5.0 grade 3 or 4 toxicities differs among African American versus non-Hispanic White breast cancer patients.

    Time frame: Up to 4 months

07

Study locations

5 of 5 sites recruiting
  • Jefferson Cherry Hill Hospital
    Cherry Hill, New Jersey 08002, United States
    Recruiting
    • Maysa Abu-Khalaf, MD · Contact215-955-8874
  • Sidney Kimmel Cancer Center Washington Township, , NJ USA
    Sewell, New Jersey 08080, United States
    Recruiting
    • Maysa Abu-Khalaf, MD · Contact215-955-8874
  • Thomas Jefferson University Hospital
    Philadelphia, Pennsylvania 19107, United States
    Recruiting
  • Jefferson Torresdale Hospital
    Philadelphia, Pennsylvania 19114, United States
    Recruiting
    • Maysa Abu-Khalaf, MD · Contact215-955-8874
  • Asplundh Cancer Pavilion
    Willow Grove, Pennsylvania 19090, United States
    Recruiting
    • Maysa Abu-Khalaf, MD · Contact215-955-8874
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2022 (actual). Primary completion is estimated for May 2027, 57 months after the start.

Of 2,668 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 57 months is above that.

Counting every sponsor, half of 2,778 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2021
First posted
Apr 14, 2022
StartActual
Jul 28, 2022
Primary completionEst.
May 1, 2027
CompletionEst.
May 1, 2027
Last update
Sep 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05327608
Responsible party
Sponsor
First posted
Apr 14, 2022
Start date
Jul 28, 2022
Primary completion
May 1, 2027 (estimated)
Completion
May 1, 2027 (estimated)
Last update
Sep 3, 2026

Study contacts

Site Public Contact
Contact
ONCTrialNow@jefferson.edu
215-600-9151
Maysa Abu-Khalaf, MD, MBA
principal investigator · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion